We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With Prestige Consumer Healthcare (PBH) Q1 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that Prestige Consumer Healthcare (PBH - Free Report) will announce quarterly earnings of $1.01 per share in its forthcoming report, representing an increase of 12.2% year over year. Revenues are projected to reach $261.91 million, declining 2% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Prestige Consumer Healthcare metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts predict that the 'Revenues- OTC Healthcare- International' will reach $35.01 million. The estimate points to a change of +0.5% from the year-ago quarter.
The consensus estimate for 'Revenues- OTC Healthcare- North American' stands at $225.14 million. The estimate suggests a change of -3.1% year over year.
Analysts forecast 'Gross profit- OTC Healthcare- North American' to reach $125.39 million. Compared to the present estimate, the company reported $126.76 million in the same quarter last year.
The average prediction of analysts places 'Gross profit- OTC Healthcare- International' at $19.90 million. The estimate compares to the year-ago value of $19.27 million.
Shares of Prestige Consumer Healthcare have demonstrated returns of -5.8% over the past month compared to the Zacks S&P 500 composite's +0.5% change. With a Zacks Rank #4 (Sell), PBH is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stay Ahead of the Game With Prestige Consumer Healthcare (PBH) Q1 Earnings: Wall Street's Insights on Key Metrics
Analysts on Wall Street project that Prestige Consumer Healthcare (PBH - Free Report) will announce quarterly earnings of $1.01 per share in its forthcoming report, representing an increase of 12.2% year over year. Revenues are projected to reach $261.91 million, declining 2% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Prestige Consumer Healthcare metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts predict that the 'Revenues- OTC Healthcare- International' will reach $35.01 million. The estimate points to a change of +0.5% from the year-ago quarter.
The consensus estimate for 'Revenues- OTC Healthcare- North American' stands at $225.14 million. The estimate suggests a change of -3.1% year over year.
Analysts forecast 'Gross profit- OTC Healthcare- North American' to reach $125.39 million. Compared to the present estimate, the company reported $126.76 million in the same quarter last year.
The average prediction of analysts places 'Gross profit- OTC Healthcare- International' at $19.90 million. The estimate compares to the year-ago value of $19.27 million.
View all Key Company Metrics for Prestige Consumer Healthcare here>>>Shares of Prestige Consumer Healthcare have demonstrated returns of -5.8% over the past month compared to the Zacks S&P 500 composite's +0.5% change. With a Zacks Rank #4 (Sell), PBH is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .